# Assessment of Right Ventricular Function by Speckle Tracking Echocardiography in Patients with COVID - 19

Mahmoud Kamel Ahmed<sup>1</sup>, Suzy Salah Lasheen<sup>1</sup>, Ramy Ali Abd-Elhameed Dawood<sup>1\*</sup>

<sup>1</sup>Department of cardiology, Faculty of Medicine, Menofia University, Menoufia, Egypt

\*Corresponding Author: Ramy Ali Abd-Elhameed Dawood, Email: Ramyali202020@gmail.com, Mobile: +201097846543

#### **ABSTRACT**

**Background:** Coronavirus disease 2019 (COVID-19) is one of the most serious problems nowadays, it is a contagious illness triggered by SARS-CoV-2.

**Aim of work:** This study aimed to investigate the influence of active COVID-19 infection on right ventricular mechanics using speckle tracking echocardiography.

**Subjects & methods:** This was observational (cross-sectional) research that that was conducted in Agouza Specialized Hospital (which turned to isolation hospital after COVID – 19 pandemic) and Cardiology Department, Menoufia University Hospitals through the period from November 2021 to January 2023. The research was carried out on 50 admitted cases with confirmed COVID 19 infection.

**Result:** There was a significant affection of RV GLS in cases with severe covid-19 infection. A significant variance was observed among groups regarding CT severity index, the more severity of CT, the more affection of RV GLS. There was a significant relation between affection of RV GLS and presence of risk factors (DM and HTN).

**Conclusion:** Our results showed that there was subclinical impairment of RV function with 2D STE in cases infected with COVID-19 in relation to the degree of pneumonia.

Key words: Right ventricular function, Speckle tracking echocardiography, COVID - 19.

#### INTRODUCTION

COVID-19 is a respiratory disorder triggered via the SARS-CoV-2 virus that has been correlated with a wide range of cardiovascular complications, involving heart failure, myocarditis, and arrhythmias. Speckle tracking echocardiography is a non-invasive imaging technique utilized to evaluate cardiac function by measuring the deformation of myocardial tissue during the cardiac cycle. The year 2020 has been overshadowed by the global COVID-19 pandemic that has a profound influence on public health. The World Health Organization (WHO) stated over 762 million validated etiology of COVID-19, involving 6.8 million deaths, as of May 2023 [WHO Coronavirus (COVID-19) Dashboard with Vaccination Data, n.d.]. To combat the virus, more than 13 billion vaccine doses have been administered (1).

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for Coronavirus disease 2019, hasn't only affected the respiratory system but also showed implications for cardiovascular health. Increasing proof recommends that COVID-related cardiovascular illness have important role in illness progression and case results (2).

The objective of this work was to examine the effect of active COVID-19 infection on right ventricular mechanics applying speckle tracking echocardiography.

#### PATIENTS AND METHODS

This was an observational (cross-sectional) investigation that was conducted in Agouza Specialized Hospital (which turned to isolation hospital after COVID – 19 pandemic) and Cardiology Department, Menoufia University Hospitals through the period from November 2021 to January 2023. The research was

carried out on 50 admitted patients with confirmed COVID 19 infection.

**Inclusion criteria:** Both females and males above the age of eighteen years old with confirmed positive PCR swap for COVID -19 infection and with moderate to severe chest CT affection as mentioned in C.T severity score in the study.

Exclusion criteria: Patients with primary pulmonary diseases (e.g.: IPF, COPD, bronchial asthma, etc.). History or any evidence of myocardial ischemia. Valvular affection more than mild form. Congenital heart diseases both cyanotic and acyanotic. History of cardiomyopathy of any type. Poor echogenic window. Any type of witnessed arrhythmia. Pericardial diseases.

#### **Methods:**

**Tools:** All patients have been subjected to the following:

**A. Complete history taking:** Including age & detailed history of cardiovascular risk factors (Hypertension, Diabetes mellitus, Hyperlipidemia and Smoking).

# **B.** Full clinical examination:

**1-General examination** involving Height, Weight, Body mass index [The body mass index (BMI) evaluates body weight relative to body height (Body weight in Kilograms/Body height in square meters) expressed in Kg/m². underweight when below 18.5, overweight when above and above 30 is considered obese]. Heart rate obtained by manual palpatory method and EKG. Blood pressure both systolic and diastolic: Hypertension is described as office SBP values not less than 140 millimeters of

Received: 20/06/2025 Accepted: 22/08/2025 mercury and/or diastolic BP (DBP) values not less than 90 millimeters of mercury. Oxygen saturation obtained by pulse oximeter on room air.

- **2-Cardiac examination** including inspection, palpation of cardiac areas, auscultation (S1 + S2) and added heart sounds if present. Murmurs if present. Presence of pericardial rub or not. Air entry of both lungs for crepitations and wheezes.
- **C. Routine laboratory investigations for COVID 19 severity affection** including inflammatory markers as following CBC with lymphopenia, serum D-dimer, CRP, serum IL-6 and serum ferritin.
- **D.** Routine 12-lead surface ECG for all admitted patients.
- E. Confirmed positive PCR swab for COVID-19 virus for all admitted patients, which was nasopharyngeal swap by RT-PCR technique obtained by trained health care personnel and tested in ministry of health central labs and patient is enrolled in such study if positive.
- **F. Chest C.T. assessment:** All patients did C.T chest after arrival to hospital (Toshiba Aquilion 64 slice) and the result was analyzed by 2 scores for batter assessment:

Typical findings for Coronavirus disease 2019:

ıcuı	indings for Coronavirus discuse	2017.
-	Ground glass opacification	88%
-	Bilateral involvement	88%
-	Posterior distribution	80%
-	Multilobular involvement	79%
-	Peripheral distribution	76%

- Consolidations 32%

# Conventional echocardiography:

- 1- Routine transthoracic echocardiograph (TTE) was done using 2D imaging, color Doppler, M-Mode, PW and CW for all patients.
- **2-** TTE examination was done while patient was supine on left lateral position connected with single lead ECG cable.
- **3-** Three successive cardiac cycles were acquired for apical four-chamber view for obtaining RV longitudinal view.

# ♦ 2D analysis:

All required conventional echocardiographic data were taken using basic parasternal, apical and subcostal views for:

- 1- Chamber size and function quantification.
- **2-** Valvular morphology and function assessment.
- **3-** Great vessels measurements and assessment.
- ♦ Conventional M-mode: for measurement of LV dimensions, fraction shortening and ejection fraction, TAPSE (tricuspid annular plane systolic excursion) obtained in apical four by putting M-Mode curser on lateral part of tricuspid valve annulus and MAPSE (mitral annular plane systolic excursion obtained also in apical four chamber view by putting M-Mode curser on lateral part of mitral valve annulus. An example of MAPSE and TAPSE measured in a patient using M-mode in apical four chamber view [Figure 1]




Figure (1): TAPSE and MAPSE.

♦ <u>Color CW and PW Doppler</u> PW Doppler for assessment of mitral valve flow and diastolic function also aortic valve flow and VTI for event timing and velocity, CW on tricuspid valve for assessment of PHT and presence of TR or PR. A sample of mitral inflow pattern in a patient with pseudonormal pattern (diastolic dysfunction grade II) with normal E/A ratio and reversed ratio with Valsalva maneuver [Figure 2].




Figure (2): Color CW and PW Doppler.

- <u>Tissue Doppler imaging (TDI):</u> The procedure was carried out through activating the pulsed wave tissue Doppler function in the apical four-chamber view and locating a sample volume of five millimeters over the medial mitral annulus. 3 main myocardial velocities have been documented at the mitral annulus:
- The peak of major positive systolic velocity when the annulus moved towards the apex called (S).
- An early peak of major negative velocity throughout early diastolic filling when the annulus moved towards the base named (e').
- Another peak of negative velocity happening throughout late diastolic filling called (a') velocity was measured. A sample of TDI of a patient with normal diastolic function denoting S wave (peak of major positive systolic velocity), e' (early peak of major negative velocity) and a' (another peak of negative velocity) [Figure 3].




Figure (3): Tissue Doppler imaging.

### G. Two dimensional speckle tracking analysis for right ventricle:

**RV longitudinal strain:** Longitudinal strain represents the shortening in systole (change in length) represented as a negative strain value of the myocardium along the long axis of the RV. The RV longitudinal strain was determined in apical four-chamber by estimating the longitudinal strain for IVS & right ventricular free wall [Figure 4].




Figure (4): RV longitudinal strain determined in apical 4-chamber view.

# Statistical analysis and data interpretation:

Information analysis has been carried out by SPSS software version 25 (SPSS Inc., PASW statistics for windows version 25, Chicago). Qualitative data were described using number and percent. Quantitative data were described using median (minimum and maximum) for non-normally distributed data and mean  $\pm$  standard deviation for normally distributed data after testing normality using Kolmogorov-Smirnov test. Significance of the obtained results was judged at  $\leq 0.05$  level.

- 1- Fischer exact, Chi-Square test & Monte Carlo tests were utilized to compare qualitative information among groups as suitable
- 2- Mann Whitney U & Kruskal Wallis test were applied to compare among two examined groups and above two examined groups, correspondingly for non-normally distributed information.
- 3- Student t test was applied to compare two independent groups for normally distributed information.
- 4- One Way ANOVA test was utilized to compare over 2 independent groups with Post Hoc Tukey test to notice pairwise comparison
- 5- The Spearman's rank-order association was applied to calculate the direction and strength of a linear correlation among 2 non-normally distributed continuous parameters.

Ethical Approval: The research was approved by The Ethics Committee of Cardiology Department, Faculty of Medicine, Menoufia University, Egypt. All participants gave written informed consents before enrolment. The research adhered to the Helsinki Declaration throughout its execution.

#### **RESULTS**

Table (1) demonstrated the comparison of conventional echocardiographic parameters between three chest CT score-groups. There were statistically significant variances in **FS** and **LVEF** between patients of group **A** (CT score 3) and patients of group **C** (CT score 5) with significantly lower **FS** and **LVEF** in group **C** and between patients of group **B** (CT score 4) and patients of group **C** (CT score 5) with significantly lower **FS** and **LVEF** in group **C**. Also, there was statistically significant difference in **TAPSE** between group **B** patients (CT score 4) and group **C** patients (CT score 5) with significantly lower **TAPSE** in group **C**. A statistically insignificant variances was observed among the groups regarding resting parameters.

**Table (1):** Conventional echocardiographic findings in CT score-based groups of the studied cases

Group A (Score 3) (Score 4) (Score 5)		CT chest score		Test of	within group	
CScore 3   CScore 4   CScore 5					significance	significance
Mean   36.62±4.07   36.71±5.29   36.01±4.24   F=0.120   p1=0.960   p2=0.703   p3=0.655   p3=0.655   p3=0.655   p3=0.655   p3=0.655   p3=0.718   p3=0.978   p3=0.978   p3=0.978   p3=0.978   p3=0.978   p3=0.978   p3=0.978   p3=0.978   p3=0.978   p3=0.989   p3=0.998   p3=0.999   p3=0.115   p3=0.115   p3=0.868   p3=0.998   p3=0.998   p3=0.998   p3=0.998   p3=0.999   p3=0.115   p3=0.868   p3=0.989   p3=0.998   p3=0.999   p3=0.115   p3=0.868   p3=0.989   p3=0.989   p3=0.997   p3=0.115   p3=0.868   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.997   p3=0.115   p3=0.868   p3=0.988			_	•		
LA   36.62±4.07   36.71±5.29   36.01±4.24   F=0.120   p1=0.960   p2=0.703   p3=0.655   p3=0.970   p3=0.970   p3=0.970   p3=0.970   p3=0.970   p3=0.970   p3=0.970   p3=0.970   p3=0.989   p3=0.985   p3=0.915   p3=0.098   p3=0.997   p3=0.868   p3=0.915   p3=0.0997   p3=0.868   p3=0.915   p3=0.0997   p3=0.868   p3=0.915   p3=0.0997   p3=0.868   p3=0.915   p3=0.0018   p3			(Score 4)	(Score 5)		
Aorta 29.26±3.51 28.03±4.03 29.75±3.92 F=0.918 p2-0.033 p3=0.655  Aorta 29.26±3.51 28.03±4.03 29.75±3.92 F=0.918 p2-0.370 p3=0.192  LVEDD 51.31±4.77 48.85±4.59 48.83±6.56 F=1.08 p1=0.208 p2=0.918 p3=0.989  LVESD 32.77±4.08 29.98±4.11 32.77±6.61 F=1.65 p1=0.133 p3=0.989  LVESD 9.5±1.78 9.6±1.83 9.4±1.91 KW=0.047 p3=0.915 p1=0.835 p2=0.997 p3=0.115  LVPWD 9.5±1.78 9.6±1.83 9.4±1.91 KW=0.283 p1=1.0 p2=0.971 p3=0.868 p3=0.715 p1=0.835 p2=0.971 p3=0.868 p3=0.715 p1=0.835 p2=0.971 p3=0.868 p3=0.715 p1=0.835 p2=0.971 p3=0.868 p3=0.715 p1=0.835 p2=0.989 p1=0.763 p2=0.991 p3=0.901						
Page	LA	$36.62 \pm 4.07$	36.71±5.29	36.01±4.24		
Aorta         29.26±3.51         28.03±4.03         29.75±3.92         F=0.918 P=0.406 P=0.406 p2=0.718 p3=0.192 p2=0.718 p3=0.192           LVEDD         51.31±4.77         48.85±4.59         48.83±6.56         F=1.08 P=0.347 p3=0.198 p2=0.198 p3=0.089 p2=0.198 p3=0.989 p3=0.989 p3=0.989 p3=0.989 p3=0.989 p3=0.989 p3=0.185 p3=0.115           LVESD         32.77±4.08         29.98±4.11         32.77±6.61         F=1.65 p1=0.133 p3=0.115 p1=0.133 p3=0.115 p3=0.868 p3=0.115 p1=0.835 p3=0.115 p3=0.868 p3=0.977 p3=0.115 p3=0.868 p3=0.115 p1=0.858 p3=0.115 p1=0.888 p2=0.9868 p3=0.586 p3=0.115 p1=0.137 p3=0.868 p3=0.018 p1=0.018 p3=0.001* p					P=0.887	
LVEDD						•
LVEDD   51.31±4.77   48.85±4.59   48.83±6.56   F=1.08   p1=0.208   p3=0.192   p1=0.208   p3=0.198   p3=0.198   p3=0.198   p3=0.198   p3=0.198   p3=0.198   p3=0.198   p3=0.113   p3=0.115   p3=0.868   p3=0.715   p3=0.868	Aorta	29.26±3.51	28.03±4.03	29.75±3.92	F=0.918	p1=0.370
LVEDD   51.31±4.77					P=0.406	p2=0.718
LVESD   32.77±4.08   29.98±4.11   32.77±6.61   F=1.65   p1=0.133   p2=0.997   p3=0.115   p1=0.835   p2=0.997   p3=0.115   p1=0.835   p2=0.997   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.997   p3=0.115   p3=0.985   p2=0.997   p3=0.115   p3=0.868   p3=0.997   p3=0.868   p3=0.715   p3=0.868   p3=0.868   p3=0.715   p3=0.868						p3=0.192
LVESD   32.77±4.08   29.98±4.11   32.77±6.61   F=1.65   p1=0.133   p2=0.997   p3=0.115   p1=0.835   p2=0.997   p3=0.115   p1=0.835   p2=0.997   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.989   p3=0.997   p3=0.115   p3=0.985   p2=0.997   p3=0.115   p3=0.868   p3=0.997   p3=0.868   p3=0.715   p3=0.868	LVEDD	51.31±4.77	48.85±4.59	48.83±6.56	F=1.08	
LVESD 32.77±4.08   29.98±4.11   32.77±6.61   F=1.65   p1-0.133   p2-0.097   p3-0.115   p2-0.097   p3-0.868   p3-0.715   p3-0.868   p3-0.018   p3-0.001*   p3-0.					P=0.347	-
LVESD         32.77±4.08         29.98±4.11         32.77±6.61         F=1.65 P=0.20 pl=0.133 p2=0.997 p3=0.115           IVSD         9.5±1.78         9.6±1.83         9.4±1.91         KW=0.047 P=0.977 p2=0.971 p3=0.868           LVPWD         9.5±1.78         9.6±1.83         9.4±1.91         KW=0.283 P=0.997 p3=0.868 p3=0.868           LVPWD         9.5±1.78         9.6±1.83         9.4±1.91         KW=0.283 P=0.928 p1=1.0 p2=0.866 p3=0.901s p3=0.901s p3=0.901s p3=0.901s p1=0.317 p2=0.02* p3=0.901* p2=0.00* p3=0.901* p1=0.763 p2=0.001* p3=0.901* p1=0.850 p3=0.248 p3=0			<u> </u>			-
P=0.203	LVESD	32.77±4.08	29.98±4.11	32.77±6.61	F=1.65	*
NSD						•
IVSD			ı			
P=0.977   p2=0.971   p3=0.868	IVSD	9.5±1.78	9.6±1.83	9.4+1.91	KW=0.047	
LVPWD   9.5±1.78   9.6±1.83   9.4±1.91   KW=0.283   p=1.0   p2-0.586   p3=0.715	1,02	). <u></u>		J. 1—1.7 =		_
LVPWD         9.5±1.78         9.6±1.83         9.4±1.91         KW=0.283 P=0.868         p1=1.0 p≥0.586 p3=0.715           FS         36.86±5.13         38.68±4.53         32.66±5.53         F=6.45 P=0.003*         p1=0.317 p2=0.02* p3=0.001*           LVEF         66.80±3.86         67.47±4.98         55.55±8.50         F=19.92 P<0.001*         p1=0.763 p2=0.001* p3=0.001*           E velocity         67.72±30.21         69.72±32.35         65.72±33.64         KW=3.01 P=0.222         p1=0.980 p2=0.068 p3=0.248           A velocity         61.87±15.41         61.59±16.12         65.81±19.62         F=0.325 P=0.724 p2=0.517 p3=0.473         p1=0.964 p2=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27         F=1.74 P=0.187 p2=0.133 p3=0.103         p1=0.941 p2=0.331 p3=0.103           e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 (-13.24,-6.27)         KW=3.05 P=0.217 p2=0.337 p3=0.102           E/e'         9 8.02 (-15.37,-3.17)         7.94 (-13.24,-6.27)         KW=0.671 p2=0.480 p3=0.908           TR PG         23.6(13.98-31.8)         38.33(63.345.4)         KW=0.693 p2=0.480 p3=0.908         p1=0.820 p2=0.857 p2=0.857 p2=0.857 p3=0.362           Basal RVD         36.33±3.07         37.14±8.88         39.96±5.58         F=0.666 p1=0.296 p2=0.857 p2=0.857 p3=0.362	ı		ı		1 - 0.2 , .	_
FS 36.86±5.13 38.68±4.53 32.66±5.53 F=6.45 p1=0.317 p2=0.02* p3=0.001*  LVEF 66.80±3.86 67.47±4.98 55.55±8.50 F=19.92 p1=0.763 p2=0.001* p3=0.001*  E velocity 67.72±30.21 69.72±32.35 65.72±33.64 KW=3.01 p1=0.850 p2=0.068 p3=0.248  A velocity 61.87±15.41 61.59±16.12 65.81±19.62 F=0.325 p1=0.964 p2=0.517 p3=0.473  E/A 1.25±0.35 1.26±0.43 1.06±0.27 F=1.74 p1=0.941 p2=0.133 p3=0.103  e' -8.72 -11.18 -7.63 KW=3.05 p1=0.344 p2=0.133 p3=0.103  e' -8.72 (-13.37,-3.17) (-14.2,-3.17) (-13.24,-6.27) P=0.217 p2=0.337 p3=0.102  E/e' 9 8.02 7.94 KW=0.671 p1=0.447 p2=0.480 p3=0.908  TR PG 23.6(13.98-31.8) 38.33(36.3-45.4) KW=0.693 p1=0.820 p2=0.908  TR PG 23.6(13.98-31.8) 38.33(36.3-45.4) KW=0.693 p1=0.820 p2=0.788 p3=0.345  Basal RVD 8 1.99±0.37 1.66±0.29 F=4.13 p=0.02* p2=0.066	I VPWD	9 5+1 78	9 6+1 83	9 Δ+1 91	KW=0 283	
FS 36.86±5.13 38.68±4.53 32.66±5.53 F=6.45 P=0.003* p1=0.317 p2=0.001* p3=0.001* p1=0.763 p2=0.001* p3=0.001* p1=0.763 p2=0.001* p1=0.763 p2=0.001* p3=0.001* p1=0.850 p2=0.001* p1=0.850 p2=0.008 p3=0.248 p1=0.222 p2=0.068 p3=0.248 p2=0.068 p3=0.248 p2=0.17 p2=0.017 p3=0.17 p3=0.103 p2=0.001* p1=0.850 p2=0.068 p3=0.248 p3=0.248 p3=0.248 p3=0.248 p3=0.248 p3=0.248 p3=0.248 p3=0.248 p3=0.248 p3=0.249 p3=0.37 p3=0.103		7.5-1.70	7.0±1.03	ノ・マニュ・ノェ		_
FS         36.86±5.13         38.68±4.53         32.66±5.53         F=6.45 P=0.003*         p1=0.317 p2=0.02* p3=0.001*           LVEF         66.80±3.86         67.47±4.98         55.55±8.50         F=19.92 P<0.001*         p1=0.763 p2=0.001*           E velocity         67.72±30.21         69.72±32.35         65.72±33.64         KW=3.01 P=0.222 P=0.068 p3=0.048           A velocity         61.87±15.41         61.59±16.12         65.81±19.62         F=0.325 P=0.724 P=0.517 p3=0.473         p1=0.964 P=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27         F=1.74 P=0.187 p2=0.133 p3=0.103         p1=0.941 p2=0.133 p3=0.103           e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 KW=3.05 P=0.217 p2=0.337 p3=0.102         p1=0.473 p2=0.480 p3=0.102           E/e'         9 (5.07-19.61)         (4.52-17.03)         (4.5-15.88)         P=0.715 p2=0.480 p3=0.908           TR PG         23.6(13.98-31.8)         25.75(13.98-31.8)         38.33(36.3-45.4)         KW=0.693 p2=0.758 p3=0.345         p1=0.296 p2=0.857 p3=0.362           Basal RVD         36.33±3.07         37.14±8.88         39.96±5.58         F=0.666 P=0.519 p2=0.857 p3=0.362           TAPSE         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 p=0.02*         p2=0.045				ļ	1 -0.000	*
LVEF         66.80±3.86         67.47±4.98         55.55±8.50         F=19.92 P<0.001*         p1=0.763 p2=0.001*           E velocity         67.72±30.21         69.72±32.35         65.72±33.64         KW=3.01 P=0.222         p1=0.850 p2=0.068 p3=0.248           A velocity         61.87±15.41         61.59±16.12         65.81±19.62         F=0.325 P=0.724 p2=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27         F=1.74 P=0.187 p2=0.133 p3=0.103         p1=0.941 p2=0.337 p3=0.103           e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 (-13.24,-6.27)         KW=3.05 P=0.217 p2=0.337 p3=0.102         p1=0.344 P2=0.337 p3=0.102           E/e'         9 (5.07-19.61)         (4.52-17.03)         (4.5-15.88)         P=0.715 p2=0.480 p3=0.908           TR PG         23.6(13.98-31.8)         38.33(36.3-45.4)         KW=0.693 p2=0.758 p3=0.345         p1=0.820 p2=0.758 p3=0.345           Basal RVD         36.33±3.07         37.14±8.88         39.96±5.58         F=0.666 P=0.519 p2=0.857 p3=0.362           TAPSE         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 p=0.02*         p2=0.06	FC	36 86±5 13	38 68+A 53	22 66+5 53	F-6 15	•
LVEF         66.80±3.86         67.47±4.98         55.55±8.50         F=19.92 P<.0001*         p1=0.763 p2=0.001* p2=0.001* p3=0.001*           E velocity         67.72±30.21         69.72±32.35         65.72±33.64         KW=3.01 P=0.222 p2=0.068 p3=0.248           A velocity         61.87±15.41         61.59±16.12         65.81±19.62         F=0.325 P=0.724 p2=0.517 p3=0.473         p1=0.964 p2=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27         F=1.74 P=0.187 p3=0.103 p3=0.103 p3=0.103         P=0.187 p3=0.473 p3=0.103 p3=0.103           e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 (-13.24,-6.27)         KW=3.05 p1=0.344 p2=0.337 p3=0.102           E/e'         9 (5.07-19.61)         8.02 (4.52-17.03)         7.94 (4.5-15.88)         KW=0.671 p1=0.473 p2=0.480 p3=0.908 p3=0.908 p3=0.908           TR PG         23.6(13.98-31.8)         38.33(36.3-45.4) S3.3(36.3-45.4) S3.2(36.3-45.4) S3.2(36.3-45.4) S3.2(36.3-45.4) S3.2(36.3-45.4) P=0.519 p2=0.758 p3=0.345         P=0.519 p2=0.758 p3=0.362           Basal RVD         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 p1=0.450 p2=0.06           TAPSE         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 p1=0.450 p2=0.06	FS	30.60±3.13	30.00±4.33	34.00±J.JJ		
LVEF       66.80±3.86       67.47±4.98       55.55±8.50       F=19.92 P<0.001*       p1=0.763 p2=0.001*         E velocity       67.72±30.21       69.72±32.35       65.72±33.64       KW=3.01 P=0.222 P≥-0.068 p3=0.048         A velocity       61.87±15.41       61.59±16.12       65.81±19.62 P=0.325 P=0.325 P=0.064 P=0.724 P=0.174 P=0.187 P3=0.473 P=0.187 P3=0.473 P=0.187 P3=0.103 P=0.187 P3=0.103 P=0.187 P3=0.103 P=0.187 P3=0.103 P=0.187 P3=0.103 P=0.187 P3=0.103 P=0.187 P3=0.102 P=0.217 P3=0.102 P=0.217 P3=0.102 P=0.217 P3=0.102 P=0.217 P3=0.102 P=0.217 P3=0.102 P=0.217 P3=0.102 P=0.473 P3=0.102 P=0.473 P3=0.102 P=0.480 P3=0.908 P3=0.908 P3=0.908 P3=0.908 P3=0.908 P3=0.908 P3=0.908 P3=0.908 P3=0.345 P=0.707 P3=0.362 P=0.519 P3=0.362 P3=0.06         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13 P=0.02* P3=0.06	ı		ı		F=0.005	
E velocity 67.72±30.21 69.72±32.35 65.72±33.64 KW=3.01 p1=0.850 p2=0.068 p3=0.248  A velocity 61.87±15.41 61.59±16.12 65.81±19.62 F=0.325 p1=0.964 p2=0.517 p3=0.473  E/A 1.25±0.35 1.26±0.43 1.06±0.27 F=1.74 p1=0.941 p2=0.133 p3=0.103  e' -8.72 -11.18 -7.63 KW=3.05 p1=0.344 (-13.37,-3.17) (-14.2,-3.17) (-13.24,-6.27) P=0.217 p2=0.337 p3=0.102  E/e' 9 8.02 7.94 KW=0.671 p1=0.473 p2=0.480 p3=0.908  TR PG 23.6(13.98-31.8) 38.33(36.3-45.4) KW=0.693 p1=0.820 p3=0.908  TR PG 23.6(13.98-31.8) 38.33(36.3-45.4) KW=0.693 p1=0.820 p3=0.345 p3=0.345  Basal RVD 36.33±3.07 37.14±8.88 39.96±5.58 F=0.666 p1=0.296 p2=0.857 p3=0.362  TAPSE 1.89±0.38 1.99±0.37 1.66±0.29 F=4.13 p1=0.450 p2=0.06	TTOET	66 0U F3 86	67 17 L1 08	FE	E-10 02	
E velocity         67.72±30.21         69.72±32.35         65.72±33.64         KW=3.01 P=0.222 P=0.068 p3=0.048           A velocity         61.87±15.41         61.59±16.12         65.81±19.62         F=0.325 P=0.724 P=0.724 P=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27         F=1.74 P=0.187 P=0.187 p2=0.133 p3=0.103           e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 KW=3.05 P=0.217 p2=0.337 p3=0.102         P=0.217 p2=0.337 p3=0.102           E/e'         9 (5.07-19.61)         8.02 (4.5-15.88)         7.94 KW=0.671 P=0.715 p2=0.480 p3=0.908 p1=0.820 p3=0.908           TR PG         23.6(13.98-31.8)         25.75(13.98-31.8)         38.33(36.3-45.4) KW=0.693 p1=0.820 p2=0.758 p3=0.345 p2=0.758 p3=0.345           Basal RVD         36.33±3.07         37.14±8.88         39.96±5.58         F=0.666 P=0.519 p2=0.857 p3=0.362 p2=0.857 p3=0.362           TAPSE         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 p1=0.450 p2=0.06	LVEF	00.80±3.60	0/.4/ <del>±4</del> .20	პპ.პა±ი.ა∪		_
E velocity         67.72±30.21         69.72±32.35         65.72±33.64         KW=3.01 P=0.222 P=2.068 p3=0.248           A velocity         61.87±15.41         61.59±16.12         65.81±19.62 P=0.724 P=0.724 P=0.724 p2=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27 P=0.187 P=0.187 p3=0.473 p3=0.103 p3=0.103           e'         -8.72 (-13.37, -3.17) (-14.2, -3.17) (-14.2, -3.17) (-13.24, -6.27) P=0.217 p2=0.337 p3=0.102         KW=3.05 P=0.217 p2=0.337 p3=0.102 p2=0.337 p3=0.102           E/e'         9 (5.07-19.61) (4.52-17.03) (4.5-15.88) P=0.715 p2=0.480 p3=0.908         KW=0.671 p1=0.473 p2=0.480 p3=0.908 p3=0.908           TR PG         23.6(13.98-31.8) 36.33±3.07 37.14±8.88 39.96±5.58 P=0.666 p1=0.820 p2=0.758 p3=0.345 p3=0.362         F=0.666 p1=0.296 p2=0.857 p3=0.362           TAPSE         1.89±0.38 1.99±0.37 1.66±0.29 F=4.13 p1=0.450 p2=0.06         F=4.13 p1=0.450 p2=0.06				ļ	P<0.001	1 -
A velocity       61.87±15.41       61.59±16.12       65.81±19.62       F=0.325 P=0.724       p1=0.964 p2=0.517 p3=0.473         E/A       1.25±0.35       1.26±0.43       1.06±0.27       F=1.74 P=0.187       p1=0.941 p2=0.133 p3=0.103         e'       -8.72 (-13.37,-3.17)       -11.18 (-14.2,-3.17)       -7.63 (-13.24,-6.27)       KW=3.05 P=0.217 p2=0.337 p3=0.102         E/e'       9 (5.07-19.61)       8.02 (4.52-17.03)       7.94 (4.5-15.88)       KW=0.671 P=0.715 p2=0.480 p3=0.908         TR PG       23.6(13.98-31.8)       25.75(13.98-31.8)       38.33(36.3-45.4) S3.3(36.3-45.4) p2=0.758 p3=0.345 p2=0.758 p3=0.345       KW=0.693 P=0.707 p2=0.857 p3=0.362         Basal RVD       36.33±3.07       37.14±8.88       39.96±5.58       F=0.666 P=0.519 p2=0.857 p3=0.362         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13 p1=0.450 p2=0.06	T looity	(7.70+20.21	(0.70+20.25	CE 70 : 22 64	7737 2.01	
A velocity         61.87±15.41         61.59±16.12         65.81±19.62         F=0.325 P=0.724         p1=0.964 p2=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27         F=1.74 P=0.187         p1=0.941 p2=0.133 p3=0.103           e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 (-13.24,-6.27)         KW=3.05 P=0.217 p2=0.337 p3=0.102           E/e'         9 (5.07-19.61)         8.02 (4.52-17.03)         7.94 (4.5-15.88)         KW=0.671 P=0.715 p2=0.480 p3=0.908           TR PG         23.6(13.98-31.8)         25.75(13.98-31.8)         38.33(36.3-45.4) RW=0.693 P=0.707 p2=0.758 p3=0.345         P=0.707 p2=0.758 p3=0.345           Basal RVD         36.33±3.07         37.14±8.88         39.96±5.58         F=0.666 p1=0.296 P=0.519 p2=0.887 p3=0.362           TAPSE         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 p1=0.450 p2=0.06	E velocity	6/./2±30.21	69.72±32.33	65./2±33.04		1
A velocity         61.87±15.41         61.59±16.12         65.81±19.62         F=0.325 P=0.724         p1=0.964 p2=0.517 p3=0.473           E/A         1.25±0.35         1.26±0.43         1.06±0.27         F=1.74 P=0.187         p1=0.941 p2=0.133 p3=0.103           e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 (-13.24,-6.27)         KW=3.05 P=0.217         p1=0.344 p2=0.337 p3=0.102           E/e'         9 (5.07-19.61)         8.02 (4.52-17.03)         7.94 (4.5-15.88)         KW=0.671 P=0.715 p2=0.480 p3=0.908           TR PG         23.6(13.98-31.8)         38.33(36.3-45.4)         KW=0.693 P=0.707 p2=0.758 p3=0.345         p1=0.820 P=0.707 p2=0.758 p3=0.345           Basal RVD         36.33±3.07         37.14±8.88         39.96±5.58         F=0.666 P=0.519 p2=0.857 p3=0.362           TAPSE         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 p1=0.450 p2=0.06	ı		ı		P=0.222	•
P=0.724   p2=0.517   p3=0.473	•,	71 07 17 41	51 TO 15 10	-7.01.10.60	- 0.00r	•
E/A	A velocity	61.87±15.41	61.59±16.12	65.81±19.62		-
E/A       1.25±0.35       1.26±0.43       1.06±0.27       F=1.74 P=0.187       p1=0.941 p2=0.133 p3=0.103         e'       -8.72 (-13.37,-3.17)       -11.18 (-14.2,-3.17)       -7.63 (-13.24,-6.27)       KW=3.05 P=0.217 P=0.344 P=0.217       p2=0.337 p3=0.102         E/e'       9 (5.07-19.61)       8.02 (4.52-17.03)       7.94 (4.5-15.88)       KW=0.671 P=0.473 P=0.473 P=0.715 P=0.473 P=0.715 P	ı		I		P=0.724	_
e'       -8.72 (-13.37,-3.17)       -7.63 (-13.24,-6.27)       KW=3.05 p1=0.344 p2=0.337 p3=0.102         E/e'       9 (5.07-19.61)       8.02 (4.52-17.03)       7.94 (4.5-15.88)       KW=0.671 p1=0.473 p2=0.480 p3=0.908         TR PG       23.6(13.98-31.8)       25.75(13.98-31.8)       38.33(36.3-45.4)       KW=0.693 p1=0.820 p2=0.758 p3=0.345         Basal RVD       36.33±3.07       37.14±8.88       39.96±5.58       F=0.666 p1=0.296 p2=0.857 p3=0.362         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13 p1=0.450 p2=0.06					· <b>- ,</b>	*
e' -8.72	E/A	1.25±0.35	1.26±0.43	1.06±0.27		_
e'         -8.72 (-13.37,-3.17)         -11.18 (-14.2,-3.17)         -7.63 (-13.24,-6.27)         KW=3.05 P=0.217         p1=0.344 p2=0.337 p3=0.102           E/e'         9 (5.07-19.61)         8.02 (4.52-17.03)         7.94 (4.5-15.88)         KW=0.671 P=0.715         p1=0.473 p2=0.480 p3=0.908           TR PG         23.6(13.98- 31.85)         25.75(13.98-31.8) 31.85)         38.33(36.3-45.4) P=0.707         KW=0.693 p1=0.820 p2=0.758 p3=0.345         p1=0.820 p2=0.758 p3=0.345           Basal RVD         36.33±3.07         37.14±8.88         39.96±5.58         F=0.666 P=0.519         p1=0.296 p2=0.857 p3=0.362           TAPSE         1.89±0.38         1.99±0.37         1.66±0.29         F=4.13 P=0.02*         p1=0.450 p2=0.06	ı		ı		P=0.187	•
C-13.37,-3.17    C-14.2,-3.17    C-13.24,-6.27    P=0.217   P=0.217   P=0.337 p3=0.102	<u> </u>	_				
E/e' 9 8.02 7.94 KW=0.671 p1=0.473 p2=0.480 p3=0.908  TR PG 23.6(13.98-31.8 38.33(36.3-45.4) KW=0.693 p1=0.820 p3=0.345  Basal RVD 36.33±3.07 37.14±8.88 39.96±5.58 F=0.666 p1=0.296 p2=0.857 p3=0.362  TAPSE 1.89±0.38 1.99±0.37 1.66±0.29 F=4.13 p1=0.450 p2=0.06	e'					•
E/e'       9 (5.07-19.61)       8.02 (4.52-17.03)       7.94 (4.5-15.88)       KW=0.671 p2=0.480 p3=0.908         TR PG       23.6(13.98-31.8) 31.85)       25.75(13.98-31.8) 38.33(36.3-45.4)       KW=0.693 p1=0.820 p2=0.758 p3=0.345         Basal RVD       36.33±3.07       37.14±8.88       39.96±5.58       F=0.666 p2=0.857 p3=0.362         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13 p1=0.450 p2=0.06	ı	(-13.37,-3.17)	(-14.2,-3.17)	(-13.24,-6.27)	P=0.217	•
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	<u> </u>					•
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	E/e'					-
TR PG       23.6(13.98-31.8) 31.85)       25.75(13.98-31.8) 38.33(36.3-45.4)       KW=0.693 p1=0.820 p2=0.758 p3=0.345         Basal RVD       36.33±3.07       37.14±8.88       39.96±5.58       F=0.666 p1=0.296 p2=0.857 p3=0.362         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13 p1=0.450 p2=0.06	ı	(5.07-19.61)	(4.52-17.03)	(4.5-15.88)	P=0.715	-
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	l					
Basal RVD $36.33\pm3.07$ $37.14\pm8.88$ $39.96\pm5.58$ $F=0.666$ P=0.519 $p1=0.296$ p2=0.857 p3=0.362TAPSE $1.89\pm0.38$ $1.99\pm0.37$ $1.66\pm0.29$ $F=4.13$ P=0.02* $p1=0.450$ p2=0.06	TR PG	23.6(13.98-	25.75(13.98-31.8:	38.33(36.3-45.4)	KW=0.693	p1=0.820
Basal RVD       36.33±3.07       37.14±8.88       39.96±5.58       F=0.666       p1=0.296         P=0.519       p2=0.857       p3=0.362         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13       p1=0.450         P=0.02*       p2=0.06	ı	31.85)			P=0.707	p2=0.758
Basal RVD       36.33±3.07       37.14±8.88       39.96±5.58       F=0.666       p1=0.296         P=0.519       p2=0.857       p3=0.362         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13       p1=0.450         P=0.02*       p2=0.06	ı					p3=0.345
Basal RVD       P=0.519       p2=0.857         p3=0.362       p3=0.362         TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13       p1=0.450         P=0.02*       p2=0.06		36.33±3.07	37.14±8.88	39.96±5.58	F=0.666	
TAPSE 1.89±0.38 1.99±0.37 1.66±0.29 F=4.13 p1=0.450 p2=0.06	Basal RVD		1			-
TAPSE       1.89±0.38       1.99±0.37       1.66±0.29       F=4.13       p1=0.450         P=0.02*       p2=0.06			ı			-
<b>P=0.02*</b> p2=0.06	TAPSE	1 89+0.38	1 99+0.37	1 66+0.29	F=4.13	
		1.07_0.20	1.22_0.27	1.00_0		•
10. 1-17. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	ı		I	ļ	1-0.0-	p3=0.008*

**p1:** variance among Group A & B, **p2:** variance among Group A & C, **p3:** variance among Group B & C, \*Statistically significant, **F:** One Way ANOVA test, **MC:** Monte Carlo test, **KW:** Kruskal Wallis test

Table (2) demonstrated the comparison of RV Global Longitudinal Strain (**GLS**) parameters between three chest CT score groups. There was statistically significant difference in **right ventricular GLS** between group A patients (CT score 3) and group C patients (CT score 5) and between group B patients (CT score 4) and group C patients (CT score 5).

**Table (2):** RV strain echocardiographic findings in CT score-based groups of the studied cases

	CT chest score-based groups			Test of	within group
	Group A	Group B	Group C	significance	significance
	(Score 3)	(Score 4)	(Score 5)		
	Number=15	Number =17	Number = 18		
		Mean			
GLS	-16.47±2.17	-15.53±1.62	-12.82±2.63	F=17.08	p1=0.233
				P<.001*	p2<0.001*
					p3<0.001*




Figure (1): Scatter diagram illustrating association among CT chest score and GLS.

Table (3) compared patients with hypertension vs patients without hypertension and a statistically insignificant variance has been found among studied cases according to conventional risk factors.

Table (3): Relation between echocardiographic findings and presence of hypertension among studied cases

	No Hypertension	Hypertension	Test of significance	
	N=18	N=28		
LA (mm)	35.20±4.19	37.25±4.58	t=1.59, P=0.117	
Aorta (mm)	27.99±3.01	29.69±4.21	t=1.56, P=0.125	
LVEDD (mm)	48.23±4.68	$50.47 \pm 5.80$	t=1.44, P=0.156	
LVESD (mm)	30.19±4.10	32.91±5.65	t=1.84, P=0.072	
IVSD (mm)	9.1(7.5-11)	9.7(1.1-86)	z=1.69, P=0.091	
LVPWD (mm)	9.15(7.5-11)	9.8(1.1-90)	z=1.24, P=0.214	
FS (%)	36.95±4.95	36.31±6.03	t=1.01, P=0.318	
LVEF (%)	64.45±6.84	62±9.15	t=1.02, P=0.312	
E velocity (cm/s)	72.14(40.64-124.37)	68.18(34.46-124.37)	z=0.376, P=0.707	
A velocity (cm/s)	58.51±16.19	66.32±17.13	t=1.61, P=0.113	
E/A	1.30±0.39	1.12±0.33	t=1.82, P=0.076	
e' (cm/s)	-10.02(-14.2, -3.17)	-8.32(-13.89, -3.17)	z=1.56, P=0.120	
E/e'	7.66(4.57-17.03)	8.99(4.5-19.61)	z=1.27, P=0.205	
TR PG (cm/s)	22.49(13.98-37)	32.99(23.98-45.4)	z=0.129, P=0.897	
TAPSE (cm)	1.89±0.39	1.81±0.36	t=0.708, P=0.482	
Basal RVD (cm)	35.49±3.66	35.44±8.95	t=0.029, P=0.977	
Z: Mann Whitney U test, t: Student t test				

Regarding LV strain echocardiographic findings, there was statistically significant variance in both left ventricular GLS and Global Circumferential Strain (GCS) in cases that had hypertension against cases without hypertension with significantly less negative strain parameters in cases that had hypertension against cases without hypertension (Table 4).

**Table (4):** Relation among GLS & GCS findings and presence of hypertension among studied cases

	No hypertension N=18	hypertensive N=28	Test of significance		
GLS (mean)	-15.35±2.70	-14.16±2.84	t=1.47 <b>P=0.148</b> *		
t: Student t test, χ2: Chi-Square test, *: Statistical significance					

In table (5), we compared COVID 19 cases with diabetes vs COVID 19 cases without diabetes and a statistically non-significant variance has been detected among studied cases according to conventional echocardiography parameters.

**Table (5):** Relation between echocardiographic findings and presence of diabetes among studied cases

	Non-diabetic N=11	diabetic N=39	Test of significance	
LA (mm)	36.52±4.43	36.40±4.57	t=0.075	
			P=0.940	
Aorta (mm)	29.01±4.13	29.02±3.80	t=0.009	
` ′			P=0.993	
LVEDD (mm)	30.56±4.52	32.18±5.40	t=0.109	
			P=0.914	
LVESD (mm)	66.27±7.04	$62.05\pm8.48$	t=0.906	
			P=0.369	
IVSD (mm)	9.5(1.1-12)	9.5(1.2-86)	z=0.365	
			P=0.715	
LVPWD (mm)	9.5(1.1-12)	9.5.(1.2-90)	z=0.106	
			P=0.916	
FS (%)	61.41±15.63	63.69±17.57	t=1.88	
			P=0.07	
LVEF (%)	66.27±7.04	62.05±8.49	t=1.51	
			P=0.139	
E velocity (cm/s)	74.6(53.99-107.7)	58.53(34.46-124.37)	z=1.32	
			P=0.186	
A velocity (cm/s)	61.41±15.64	63.69±17.57	t=0.389	
			P=0.699	
E/A	1.37±0.34	1.14±0.354	t=1.94	
			P=0.06	
e' (cm/s)	-11.8(-14.2, -3.17)	-8.3(-13.89, -3.17)	z=1.64	
			P=0.101	
E/e'	7.38(5.07-19.61)	8.95(4.5-17.03)	z=0.375	
			P=0.708	
TR PG (cm/s)	24.98(13.98-37)	32.33(23.98-45.4)	z=0.352	
			P=0.725	
Basal RVD (cm)	36.57±3.81	$35.14\pm8.27$	t=0.719	
			P=0.476	
TAPSE (cm)	2.04±0.357	$1.79\pm0.35$	t=2.03	
			P=0.048*	
Z: Mann Whitney U test				

Regarding LV strain echocardiographic findings, there was **statistically significant** variance in both left ventricular GLS and GCS in Coronavirus disease 2019 cases with diabetes vs Coronavirus disease 2019 patients without diabetes (Table 6).

**Table (6):** Relation between GLS & GCS findings in COVID 19 patients and presence of diabetes among studied cases

	Non-diabetic N=11	Diabetic N=39	Test of significance	
GLS	-16.29±2.73	-	t=3.26	
(mean)		13.78±2.49	P=0.002*	
t: Student t test, χ2: Chi-Square test, *Statistically significant				

### **DISCUSSION**

Significant differences were observed in fractional shortening (FS), RV GLS, and tricuspid annular plane systolic excursion (TAPSE) across different computed tomography (CT) severity stratified groups. Furthermore, there was an independent correlation between RV GLS and CT severity score, as well as between RV GCS and CT severity score, as shown in scatter diagrams.

Regarding RV GLS, we observed that 30% of patients exhibited deteriorated RV-GLS, with higher percentages found in more severe CT-score-based groups (13.3% in group A, 17.6% in group B, and 55.6% in group C) (P-value equal 0.004). Similar prevalence of abnormal RV GLS has been reported in previous studies. For instance, **Azeri** et al. (3) performed a study including 74 patients had active COVID-19 and found abnormal RV-GLS values (> -18) in 37.8% of patients (3). These results emphasize the importance of evaluating right ventricular function in cases had COVID-19, as it can provide valuable insights into disease severity and prognosis. Additional investigation is required to fully understand the influence of COVID-19 on the right side of the heart and develop appropriate management strategies for patients with cardiovascular involvement. The WASE COVID-19 research, performed on 870 cases with active COVID-19 infection from various regions, including Asia, Europe, the United States and Latin America, shed light on the association between right-sided cardiac markers and disease severity (4).

The study carried out central, blinded analyses of echocardiograms, including measurements of left ventricular ejection fraction (LVEF) and strain of the two ventricles. The results revealed that markers of both left-sided (LV GLS) and right-sided (RVFWS) function were independently associated with disease severity. Notably, the study found that LVEF didn't illustrate an independent correlation with illness degree, which differs from recently published findings by **Faridi et al.**(5). Conversely, LV GLS demonstrated an independent association, emphasizing the importance of advanced echocardiographic assessment for a comprehensive risk evaluation in COVID-19 cases. Echocardiography plays

a significant role in diagnosing and guiding clinicians towards specific diagnoses in COVID-19 patients, in addition to its association with disease severity and myocardial injury.

Other studies have also reported a strong association and a higher prevalence of abnormal echocardiographic parameters, particularly GLS, in COVID-19 patients. For instance, a study involved 218 COVID-19 patients and found a very high prevalence (80%) of abnormal RV GLS in the study population <sup>(6)</sup>. The wide range of association of strain parameters with COVID-19 infection may be attributed to different patient populations and varying severities of COVID-19 across studies. Nevertheless, these studies collectively suggest that abnormal RV GLS is indicator of increased cardiovascular risk and might be linked to worse clinical results in COVID-19 cases. The diminution in RV GLS found in COVID-19 patients could be influenced by several factors. Multiple mechanisms have been proposed to explain right ventricular involvement and myocardial injury in Coronavirus disease 2019 infection. These mechanisms include direct injury caused by myocarditis due to the binding of the SARS-CoV-2 spike protein to the ACE-2 receptor and indirect injury resulting from the cytokine inflammatory storm triggered via the immune response of the body (7). Understanding the influence of COVID-19 on the right side of the heart is crucial for risk stratification and patient management. Advanced echocardiographic assessment including strain measurements, provides valuable insights into cardiac function and helps identify individuals at higher cardiovascular risk.

Our findings provided new light on, right ventricular free wall longitudinal strain (RVFWLS) alterations in cases had confirmed COVID-19 infection. The average RVFWLS and GLS of COVID-19 cases were found to be lower than that of a healthy control group, this was the case, indicating the existence of hidden myocardial damage. Even with maintained RVFWLS, imaging techniques for identification of cardiac damage in the acute environment. Even with this improvement, there was a tendency towards predicting in-hospital mortality or the requirement for mechanical ventilation when RVFWLS decline was moderate to severe. During admission, individuals who died had considerably greater levels of inflammatory markers including D-dimer than those who survived.

Our results showed a statistically significant association (p=0.008) between TAPSE and severity according to CT chest scores, which is generally consistent with those of current investigation in intensive care unit cases with COVID-19. The major breakthrough that abnormal RVFWLS was independently linked with severity risk and was discovered in this prospective investigation of RV STE in cases had COVID-19 needing IMV the association between right ventricular (RV) free wall longitudinal strain and severity among individuals with COVID-19.

Viral infiltration of the myocardium may result in cardiomyocyte inflammation and death, affecting both the left and right sides of the heart. This mechanism of direct myocardial injury is supported by multiple researches, involving a current study by Churchill et al. (8), which found that more than half of the cases with elevated high-sensitivity troponin T (≥ 50 ng/mL) had evidence of left ventricular dysfunction. In addition to direct myocardial injury, myocardial involvement in COVID-19 may also be influenced by other factors such proinflammatory cytokines hvpoxia. microvascular dysfunction (9). These mechanisms may result in secondary myocardial injury and affect both left and right ventricular function.

Regarding inflammatory markers, studies have shown a significant elevation in serum inflammatory cytokines and markers, including serum ferritin, IL-6, D-dimer and LDH in COVID-19 cases. These indicators are closely related to a diminution in right ventricular strain variables like RV GLS and RVFWS by Bruhl et al. (10). Elevated inflammatory markers have been strongly associated with disease severity and may contribute to myocardial affection. A study by Cameli et al. (11) demonstrated a significant correlation among elevated inflammatory markers and disease severity in a study of 400 cases. Cardiovascular risk factors like hypertension and diabetes can also impact the right side of the heart. These conditions can affect the subendocardial fibers leading to left ventricular fibrotic processes and myocardial injury. Such myocardial injury is expected to have an impact on right ventricular strain parameters (12). Several studies have shown a significant reduction in right ventricular strain, including RV GLS, among patients with hypertension (13). Similarly, Ghoreyshi-Hefzabad et al. (14) demonstrated that patients with diabetes have been found to have impaired left ventricular strain parameters.

## **CONCLUSION**

We have assessed the subclinical impairment of right ventricular function with 2D STE in cases infected with COVID-19 in correlation with the degree of pneumonia. Our study suggests that assessment of right ventricular function with 2D STE in COVID-19 infected patient as compared to conventional 2D echo variables especially TAPSE, was more reliable and earlier in detection of any dysfunction. Therefore, we propose the utilization of strain variables in addition to conventional variables in order to predict the prognosis and result of cases having a COVID-19 infection regarding RV function.

## **DECLARATIONS**

**Consent for publication:** I certify that each author has granted permission for the work to be submitted.

**Funding:** No fund.

Availability of data & material: Available.

**Conflicts of interest:** None. **Competing interests:** None.

#### REFERENCES

- **1- McErlane J, McCall P, Willder J** *et al.* **(2022):** Right ventricular free wall longitudinal strain is independently associated with mortality in mechanically ventilated patients with COVID-19. Ann Intensive Care, 12 (1): 104. doi: 10.1186/s13613-022-01077-7.
- **2- Roy R, McDonaugh B, O'Gallagher K (2022):** COVID-19 and the heart. Br Med Bull., 144 (1): 4-11. doi: 10.1093/bmb/ldac022.
- **3- Özer S, Candan L, Özyıldız A, Turan O (2021):** Evaluation of left ventricular global functions with speckle tracking echocardiography in patients recovered from COVID-19. International Journal of Cardiovascular Imaging, 37 (7): 2227–2233. https://doi.org/10.1007/S10554-021-02211-5/TABLES/3
- **4- Karagodin I, Carvalho Singulane C, Woodward G** *et al.* **(2021):** Echocardiographic Correlates of In-Hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study. Journal of the American Society of Echocardiography, 34 (8): 819–830.
- **5- Faridi K, Hennessey K, Shah N** *et al.* (2020): Left Ventricular Systolic Function and Inpatient Mortality in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19). In Journal of the American Society of Echocardiography, 33 (11): 1414-1415.
- **6- Li R, Wang H, Ma F** *et al.* **(2021):** Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography. Acta Pharmacol Sin., 42 (10): 1567–1574.
- **7- Huang C, Wang Y, Li X** *et al.* (2020): Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395 (10223): 497-506.
- **8- Churchill T, Bertrand P, Bernard S** *et al.* (2020): Echocardiographic Features of COVID-19 Illness and Association with Cardiac Biomarkers. J Am Soc Echocardiogr., 33 (8): 1053-1054.
- **9- Varga Z, Flammer A, Steiger P** *et al.* **(2020):** Endothelial cell infection and endotheliitis in COVID-19. Lancet Lond Engl., 395 (10234): 1417–1418.
- **10- Bruhl S, Chahal M, Khouri S (2011):** A novel approach to standard techniques in the assessment and quantification of the interventricular systolic relationship. Cardiovascular Ultrasound, 9 (1): 1–5. https://doi.org/10.1186/1476-7120-9-42/FIGURES/3
- **11- Cameli M, Mondillo S, Solari M** *et al.* **(2016):** Echocardiographic assessment of left ventricular systolic function: from ejection fraction to torsion. Heart Failure Reviews, 21 (1): 77–94.
- **12- Ikonomidis I, Tzortzis S, Triantafyllidi H** *et al.* (2015): Association of impaired left ventricular twisting-untwisting with vascular dysfunction, neurohumoral activation and impaired exercise capacity in hypertensive heart disease. European Journal of Heart Failure, 17 (12): 1240–1251.
- 13- Nagueh S, Smiseth O, Appleton C *et al.* (2016): Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 29 (4): 277–314.
- **14-Ghoreyshi-Hefzabad S, Jeyaprakash P, Vo H** *et al.* **(2023):** Subclinical systolic dysfunction detected by 2D speckle tracking echocardiography in adults with diabetes mellitus: systematic review and meta-analysis of 6668 individuals with diabetes mellitus and 7218 controls. International Journal of Cardiovascular Imaging, 39 (5): 977–989.